Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

    American Journal of Kidney Diseases Date published:

  • Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

    Nephrology Dialysis Transplantation Date published:

  • Pilot Trials in Nephrology: Establishing a BASE for Large-Scale Randomized Trials

    Journal of the American Society of Nephrology Date published:

  • Letters to the Editor: When should treatment be started for hypertension?

    Australian Prescriber Date published:

  • The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

    The Lancet Rheumatology Date published:

  • SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

    The Lancet Diabetes & Endocrinology Date published:

  • Inequities in the global representation of sites participating in large, multicentre dialysis trials: a systematic review

    BMJ Global Health Date published:

  • Varying Association of Extended Hours Dialysis with Quality of Life

    Clinical Journal of the American Society of Nephrology Date published:

  • Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey

    BMJ Date published:

  • Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

    Diabetology International Date published:

  • Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering

    Canadian Medical Association Journal Date published:

  • Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease

    JAMA Internal Medicine Date published:

  • P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease

    European Heart Journal Date published:

  • Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

    Journal of the American Society of Nephrology Date published:

  • Canagliflozin and Renal Outcomes in Diabetic Nephropathy

    New England Journal of Medicine Date published:

  • Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial

    Nephrology Dialysis Transplantation Date published: